After four days, the dose is increased to 348mg, which you would remain on
However, the dynamics shifted thereafter
Understanding your individual risk profile supports a conversation with your provider about mitigation strategies
This data can help optimize treatment plans, identify potential issues early, and celebrate milestones, fostering a more informed and engaged approach to health management
Currently, several dual GIP/GLP-1 receptor agonists are under clinical development, among which tirzepatide was approved in the United States and Europe in 2022 for the treatment of T2DM
Furthermore, individuals who consume a high amount of processed foods or those who do not drink enough water are at a higher risk of developing constipation